Brand/Development name: Antiprogestin
Company(ies): Bayer
Principal Therapy Area: Cancer
Online, PDF
Lonaprisan is a progesterone receptor antagonist, has potential as an oral treatment for advanced breast cancer, and secondary or primary breast cancer prevention.
It is in Phase II trials for second-line metastatic breast cancer with an expected completion date in April 2011. Lonaprisan was expected to be filed in the US and Europe in 2009, however, Lonaprisan is not in the January 2010 pipeline.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Cost-effective collections
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for direct_sales@espicom.com